• 제목/요약/키워드: immunosuppressive drug

검색결과 77건 처리시간 0.083초

심장이식 1례보고 (Cardiac Transplantation; 1 Case Report)

  • 송명근
    • Journal of Chest Surgery
    • /
    • 제26권3호
    • /
    • pp.224-227
    • /
    • 1993
  • We experienced one case of orthotopic cardiac transplantation in a patient with end stage dilated cardiomyopathy. This 50 year-old female recipient was suffered from NYHA functional class IV cardiac failure and dependent upon intravenous inotropic support for 2 months [recipient category 1]. Her preoperative condition was grave with left ventricular ejection fraction of 20% and estimated systolic pulmonary arterial pressure [from Doppler study] was 50mmHg. The brain-dead donor was 31 year-old male with head trauma. The body sizes [weight, height] of the donor/recipient were 70 Kg, 165 cm / 43 Kg, 160 cm and appropriately overmatched. Preoperatively, identical ABO/Rh blood group [A+] and nonreacting HLA crossmatching were confirmed. On November 11 1992 cardiac transplantation was performed without complication. Multiple organ procurement team and heart transplantation team were organized the operation schedule appropriately to minimize the ischemic time. The pump time was 126 minutes and aortic crossclamping time of recipient heart was 73 minutes and, as a result, total ischemic time of the transplanted heart was 75 minutes. Postoperatively, the vital signs were stable with minimal inotropic support. The immunosuppressive therapy was commenced from preoperatively and cyclosporine, azathioprine, and corticosteroid were used as a combination therapy as scheduled and monitored with blood drug concentration, WBC count, renal function and most importantly regular endomyocardial biopsy.Now, 5 months after transplantation, the patient is in NYHA functional class II with minimal cardiac drug support.

  • PDF

Cyclosporin A가 봉입된 nanostructured lipid carriers의 물리적 특성연구 (Physical properties of cyclosporin A-loaded nanostructured lipid carriers)

  • 송충길;정석재;심창구;김대덕
    • Journal of Pharmaceutical Investigation
    • /
    • 제38권1호
    • /
    • pp.39-43
    • /
    • 2008
  • Cyclosporin A (CyA), a potent immunosuppressive drug used in allogeneic transplants and autoimmune disease, is a typical water-insoluble drug. Recently, nanoparticle carriers were investigated to improve the intestinal absorption of drugs. In this study, CyA-loaded nanostructured lipid carriers (NLCs) were prepared from a hot o/w emulsion using the high pressure homogenization method. The NLCs were consisted of cationic lipids, solid lipids, liquid lipids (oils), surfactant and stabilizer. Encapsulation efficiency of CyA in NLCs was approximately 71%. The average particle size and zeta potential of NLCs were below 250 nm and above +40 mV, respectively. The morphology of NLCs was confirmed by transmission electron microscopy (TEM) analysis. Compared to the CyA powder, higher in vitro release of CyA from NLCs was observed after burst release within 30 min. Thus, CyA-loaded NLCs could be applied not only for parenteral route but also for gastrointestinal administration, which needs further investigation.

돼지 Balantidium증에 대한 병리학적 연구 (Pathological study on balantidiosis of pigs)

  • 양홍지;임병무;서창섭
    • 대한수의학회지
    • /
    • 제32권2호
    • /
    • pp.211-215
    • /
    • 1992
  • Fecal examination for survey of natural prevalence of Balantidium coli was performed on 1080 healthy bred pigs in Korea, and the positive rate was 56.2%. In order to observe if Balantidium coli might be a secondary invader after certain initiation of the intestinal lesions, the piglet groups preinfected with the protozoa experimentally were treated with Salmonella cholerasuis, Trichuris. cold stress, HCI, and immunosuppressive drug respectively, but no relation was found between them. Also the protozoa were not detected from the intestinal lesions spontaneously formed of 107 pigs which were checked in the slaughter house. According to the above results, Balantidium coli is not directly associated with the formation of any lesions in the pig's large intestine.

  • PDF

돼지 Balantidium증에 관한 병리학적 연구 (Pathological Study on Balantidiosis of Pigs)

  • 양홍지;윤여백;박태욱;박용석;서창섭;임병무
    • 한국동물위생학회지
    • /
    • 제15권2호
    • /
    • pp.195-202
    • /
    • 1992
  • Fecal Examination for survey of natural prevalence of Balantidium coli was performed on 1,080 healthy bred pigs in Korea, and the positive rate was 56.2%. In order to observe if Balantidium coli might be a secondary invader after certain initiation of the Intestinal lesions, the piglet groups preinfected with the protozoa experimentally were treated with salmonella cholerasuis, Trichuris, cold stress, HCI, and immunosuppressive drug respectively, but no relatios was found between them. Also the protozoa were not deteceted from the intestinal lesions spontaneously formed of 107 pigs which were checked in the slaughter house. According to the above results, Balantidium coli is not directly associated with the formation of any lesions in the pig's intestine.

  • PDF

Cyclic Peptides as Therapeutic Agents and Biochemical Tools

  • Joo, Sang-Hoon
    • Biomolecules & Therapeutics
    • /
    • 제20권1호
    • /
    • pp.19-26
    • /
    • 2012
  • There are many cyclic peptides with diverse biological activities, such as antibacterial activity, immunosuppressive activity, and anti-tumor activity, and so on. Encouraged by natural cyclic peptides with biological activity, efforts have been made to develop cyclic peptides with both genetic and synthetic methods. The genetic methods include phage display, intein-based cyclic peptides, and mRNA display. The synthetic methods involve individual synthesis, parallel synthesis, as well as split-and-pool synthesis. Recent development of cyclic peptide library based on split-and-pool synthesis allows on-bead screening, in-solution screening, and microarray screening of cyclic peptides for biological activity. Cyclic peptides will be useful as receptor agonist/antagonist, RNA binding molecule, enzyme inhibitor and so on, and more cyclic peptides will emerge as therapeutic agents and biochemical tools.

Protein-Protein Interaction between Poly(A) Polymerase and Cyclophilin A in Chemotactic Cells

  • Choi, Hyun-Sook;Kim, Hana;Lee, Changgook;Kim, Youngmi;Lee, Younghoon
    • Bulletin of the Korean Chemical Society
    • /
    • 제35권1호
    • /
    • pp.83-86
    • /
    • 2014
  • Poly(A) polymerase (PAP) play an essential role for maturation of mRNA by adding the adenylate residues at the 3' end. PAP functions are regulated through protein-protein interaction at its C-terminal region. In this study, cyclophilin A (CypA), a member of the peptidyl-prolyl cis-trans isomerase family, was identified as a partner protein interacting with the C-terminal region PAP. The interaction between PAP and CypA was inhibited by the immunosuppressive drug cyclosporine A. Deletion analysis revealed that the N-terminal 56 residues of CypA are sufficient for the interaction with PAP. Interestingly, we observed that PAP and CypA colocalize in the nucleus during SDF-1-induced chemotaxis, implying that CypA could be involved in the regulation of polyadenylation by PAP in the chemotactic cells.

Highlighted STAT3 as a potential drug target for cancer therapy

  • Lee, Haeri;Jeong, Ae Jin;Ye, Sang-Kyu
    • BMB Reports
    • /
    • 제52권7호
    • /
    • pp.415-423
    • /
    • 2019
  • Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation and immune responses. Aberrant STAT3 activation triggers tumor progression through oncogenic gene expression in numerous human cancers, leading to promote tumor malignancy. On the contrary, STAT3 activation in immune cells cause elevation of immunosuppressive factors. Accumulating evidence suggests that the tumor microenvironment closely interacts with the STAT3 signaling pathway. So, targeting STAT3 may improve tumor progression, and anti-cancer immune response. In this review, we summarized the role of STAT3 in cancer and the tumor microenvironment, and present inhibitors of STAT3 signaling cascades.

Successful long-term management of late-stage precursor-targeted immune-mediated anemia with prednisolone and mycophenolate mofetil in a dog

  • Doyun Kim;Woo-Jin Song;Sung-Soo Kim;Soyoung Jeong;Hyun Jeong Hong;Youngmin Yun
    • 대한수의학회지
    • /
    • 제63권2호
    • /
    • pp.8.1-8.3
    • /
    • 2023
  • A 13-year-old neutered male Maltese dog presented to our hospital with lethargy and anorexia. Laboratory abnormalities included severe non-regenerative anemia (hematocrit, 12.9%; reticulocyte count 12.8 K/µL). The cytology of bone marrow revealed erythroid hypercellularity with mild myelofibrosis. Therefore, late-stage precursor-targeted immune-mediated anemia (PIMA) was diagnosed. Multimodal treatment including 2 immunosuppressant drugs (prednisolone and mycophenolate mofetil), antithrombic drug (clopidogrel), and blood transfusion was performed. The dog showed complete remission from PIMA, and the total duration of follow-up was 622 days. This is the first case report of canine PIMA managed successfully with prednisolone and mycophenolate mofetil in Korea.

Introducing the general management of glomerular disease from a pediatric perspective based on the updated KDIGO guidelines

  • Seon Hee Lim
    • Childhood Kidney Diseases
    • /
    • 제27권2호
    • /
    • pp.55-63
    • /
    • 2023
  • In 2021, a new chapter on the general management of glomerulonephritis (GN) was added to the Kidney Disease: Improving Global Outcomes (KDIGO). It emphasizes the importance of early general management of GN for improving long-term kidney outcomes and prognosis. The chapter introduces the management of glomerular diseases in 18 subchapters. Here, kidney biopsy for the diagnosis and evaluation of kidney function and the management of complications, such as hypertension, infection, and thrombosis, are presented. Moreover, the adverse effects of glucocorticoids and immunosuppressive therapy, which are commonly used drugs for glomerular disease, are mentioned, and a guideline for drug selection is presented. Each subtheme focused on items reflecting the interpretation of the "practice points" of the expert working group are introduced. In this review of the general treatment for GN in the KDIGO guidelines, excluding pregnancy and reproductive health, we focused on and compared various references pertaining to pediatric GN management.

Herpes zoster ophthalmicus after COVID-19 vaccine booster in healthy younger adult: a case report

  • Zamrud Wilda Nuril Awaly
    • Clinical and Experimental Vaccine Research
    • /
    • 제12권1호
    • /
    • pp.82-84
    • /
    • 2023
  • There were growing reports of herpes zoster reactivation after the coronavirus disease 2019 (COVID-19) vaccination, including a more severe form, herpes zoster ophthalmicus (HZO). A 35-year-old male presented HZO in his left V1 dermatome 10 days after his COVID-19 vaccine booster with Moderna (messenger RNA-1273). He had no history of chronic disease, immunocompromised, autoimmune, malignancy, or long-term immunosuppressive drug use. The rash improved without any further complications after being treated with oral valacyclovir for 7 days. This was a unique case of HZO after the COVID-19 vaccine in a booster setting in healthy younger adults. The association of herpes zoster after a COVID vaccine remained inconclusive and potentially coincidental, especially without the known risk factor. However, we would like to add a report to increase awareness among physicians and the general population, for early recognition and treatment with an antiviral.